Document is current
Any future updates will be listed below
-
Authors
Nayan, Mohammad Ullah
Sillman, Brady https://orcid.org/0000-0002-7123-3034
Das, Srijanee https://orcid.org/0000-0002-2792-0718
Hanson, Brandon W. https://orcid.org/0009-0007-0740-1201
Sultana, Ashrafi https://orcid.org/0000-0003-2653-6834
Le, Nam Thai Hoang
Deodhar, Suyash
Gowda, Bhoomika
Dash, Prasanta K. https://orcid.org/0000-0002-8250-2359
Agrawal, Satish
Dash, Alekha K.
Cohen, Samuel M. https://orcid.org/0000-0002-5047-0962
Zhang, Chen https://orcid.org/0000-0002-0785-1292
Gendelman, Howard E. https://orcid.org/0000-0002-7831-0370
Edagwa, Benson https://orcid.org/0000-0003-1484-9331
-
Funding
Funding for this research was provided by:
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (R01AI145542, R01AI158160 and R01AI163042)
- License Information
-
More Information
Article History
Received: 4 February 2025
Accepted: 9 January 2026
First Online: 21 January 2026
Competing interests
: B.E. and H.E.G. are cofounders of Exavir Therapeutics, Inc. and are inventors on patents that cover ULA BIC formulations. The authors declare that this work was produced solely by the authors and that no other individuals or entities influenced any aspects of the work, including, but not limited to, the study conception and design, data acquisition, analyses, and interpretation, and writing of the manuscript. The authors further declare that they have received no financial compensation from any other third parties for any aspects of the published work. The remaining authors declare no competing interests.
